The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড$802,588 Vol.
Dec 31, 2026
September 30
2%
December 31
26%
$802,588 Vol.
September 30
$262 Vol.
2%
December 31
$192,755 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
মার্কেট ওপেন হয়েছে: Feb 7, 2026, 5:04 PM ET
ভলিউম
$802,588শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETরেজলভার
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ভলিউম
$802,588শেষ তারিখ
Jan 1, 2027মার্কেট ওপেন হয়েছে
Feb 7, 2026, 5:04 PM ETরেজলভার
0x65070BE91...The April 2026 DOJ final order, issued under President Trump’s executive directive on medical cannabis research, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act, providing tax relief under Section 280E for qualifying operators while preserving strict controls on recreational use. An expedited DEA administrative hearing on broader rescheduling from Schedule I to III ran from June 29 to July 15, 2026; post-hearing briefs, including the DEA’s own argument that marijuana no longer meets Schedule I criteria due to accepted medical use, were filed in August, with the full transcript released in early September. The presiding ALJ’s recommendation to the Administrator remains pending without a statutory deadline, alongside ongoing D.C. Circuit litigation and a narrowed hemp definition effective November 2026. These steps shape trader assessments of timelines for any further federal action.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা